A biopharmaceutical company focused exclusively on metabolic dysfunction-associated steatohepatitis (MASH), having secured ...
ALT heads into a high-stakes 2026 as pemvidutide drives key phase III and mid-stage catalysts that could reshape its ...
Actively planning for HU6’s late-stage development in MASH - - HU6 is potential best-in-class oral MASH therapy designed to address unmet needs in MASH through a unique energy expenditure approach - ...
NORCROSS, Ga., March 31, 2026 (GLOBE NEWSWIRE) -- Galectin Therapeutics, Inc. (NASDAQ: GALT), the leading developer of therapeutics that target galectin proteins, today reported financial results and ...
Jay N. Yepuri, MD, MS, FACG, is a board-certified gastroenterologist and member of the Digestive Health Associates of Texas Board of Directors and Executive Committee. MASH is the updated term for ...
QUEBEC, Feb. 19, 2026 /PRNewswire/ - Devonian Health Group Inc. ("Devonian" or the Company) (TSXV: GSD) (OTCQB: DVHGF) today announced positive results from a follow-up preclinical study evaluating ...
ThoughtSpot, the Agentic Analytics Platform company, is launching the next generation of Analyst Studio—introducing a new suite of capabilities to revolutionize how data teams deliver AI-ready data ...
Metabolic dysfunction-associated steatohepatitis, or MASH, is a disease at the intersection of metabolic and hepatic dysfunction — creating a complex clinical picture for people living with this ...
Gene expression analysis from the STAM mouse model attributes Thykamine™ with dose-dependent anti-MASH, anti-inflammatory and anti-fibrosis molecular effects in liver QUÉBEC, Feb. 12, 2026 /PRNewswire ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results